Idarucizumab
Praxbind (idarucizumab) is an antibody pharmaceutical. Idarucizumab was first approved as Praxbind on 2015-10-16. It has been approved in Europe to treat hemorrhage.
Trade Name | Praxbind |
---|---|
Common Name | Idarucizumab |
Indication | hemorrhage |
Drug Class | Monoclonal antibodies: humanized, cardiovascular indications |
